ARTICLE
17 June 2025

Fed. Cir. Invalidates Atorvastatin Hemicalcium Salt Claim

LD
Lerner David

Contributor

For the past five decades, Lerner David has thrived as an intellectual property (IP) boutique dealing with all aspects of IP. IP is not just our specialty; it is our passion and purpose. We assist a diverse client base, protecting ground-breaking technologies and safeguarding some of the world's leading brands. And we fight for our clients' rights before the courts and administrative tribunals of the world. Lerner David stands at the ready to help innovators protect and bring tomorrow's emerging technologies to life today.
The Federal Circuit, in Pfizer, Inc. v. Ranbaxy Laboratories Ltd., 457 F.3d 1284 (Fed. Cir. August. 2, 2006), reversed the District Court holding that claim 6 directed...
United States Litigation, Mediation & Arbitration

The Federal Circuit, in Pfizer, Inc. v. Ranbaxy Laboratories Ltd., 457 F.3d 1284 (Fed. Cir. August. 2, 2006), reversed the District Court holding that claim 6 directed to the hemicalicum salt of atorvastatin was valid even though it recognized there was a “technical problem” with the drafting of claim 6, because parent claim 2 recited only atorvastatin acid and the hemicalicum salt of atorvastatin acid is not an acid falling within the scope of claim 2. The Federal Circuit acknowledged that there may be ways to redraft claim 6 to cover the subject matter in a way that does not violate 112 ¶4, however the court, citing Nazomi Commc'ns, Inc. v. Arm Holdings, PLC, determined that court should not rewrite claims to preserve their validity.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More